There is uncertainty regarding the timing of recovery in certain segments, such as BioPharma and Agroscience, which could affect future growth. Eurofins' share buyback strategy may limit available ...

For 2025, Eurofins anticipates mid-single-digit organic growth, driven by recovery in biopharma and agrosciences, though growth in the first half may remain subdued. The company highlighted its ...

Eurofins reported solid financial performance for the fourth quarter of 2024, with revenues increasing by 6.7% year-on-year to nearly 6 billion euros. The company's earnings per share rose by 41%, and ...

Ladies and gentlemen, welcome, and thank you for joining Eurofins’ FY 2024 Results ... There is a number of reasons for that. Agrosciences services or crop sciences was probably the hardest ...